News articles about Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) have been trending somewhat positive recently, according to Accern. Accern identifies negative and positive news coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Verona Pharma PLC American Depositary Share earned a media sentiment score of 0.23 on Accern’s scale. Accern also assigned news coverage about the company an impact score of 45.4259743519754 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.

Several equities analysts have commented on VRNA shares. SunTrust Banks, Inc. initiated coverage on shares of Verona Pharma PLC American Depositary Share in a research report on Monday, May 22nd. They issued a “buy” rating and a $26.00 price target for the company. Jefferies Group LLC reaffirmed a “buy” rating and set a $26.00 price objective on shares of Verona Pharma PLC American Depositary Share in a research report on Monday, May 22nd. Stifel Nicolaus initiated coverage on shares of Verona Pharma PLC American Depositary Share in a research report on Monday, May 22nd. They set a “buy” rating and a $22.00 price objective for the company. Wedbush initiated coverage on shares of Verona Pharma PLC American Depositary Share in a research report on Monday, May 22nd. They set an “outperform” rating and a $25.00 price objective for the company. Finally, Zacks Investment Research raised shares of Verona Pharma PLC American Depositary Share from a “hold” rating to a “buy” rating and set a $14.00 price objective for the company in a research report on Tuesday, July 25th. Five research analysts have rated the stock with a buy rating, Verona Pharma PLC American Depositary Share currently has an average rating of “Buy” and a consensus price target of $22.60.

Shares of Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) opened at 11.80 on Monday. The firm’s market capitalization is $75.76 million. Verona Pharma PLC American Depositary Share has a 52 week low of $11.03 and a 52 week high of $17.50. The company’s 50-day moving average is $14.21 and its 200 day moving average is $14.01.

TRADEMARK VIOLATION WARNING: This piece was published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this piece on another website, it was stolen and reposted in violation of U.S. & international copyright & trademark legislation. The legal version of this piece can be viewed at https://www.thecerbatgem.com/2017/08/07/somewhat-favorable-media-coverage-somewhat-unlikely-to-impact-verona-pharma-plc-american-depositary-share-vrna-share-price-updated.html.

About Verona Pharma PLC American Depositary Share

Verona Pharma plc, a clinical stage biopharmaceutical company, researches, discovers, and develops therapeutic drugs to treat respiratory diseases primarily in the United Kingdom and North America. The company’s lead product is RPL554, an inhaled dual inhibitor of the enzymes phosphodiesterase 3 and 4, which is in Phase IIa clinical trial that acts as a bronchodilator and an anti-inflammatory agent for the treatment of chronic obstructive pulmonary disease, cystic fibrosis, and asthma.

Receive News & Stock Ratings for Verona Pharma PLC American Depositary Share Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verona Pharma PLC American Depositary Share and related stocks with our FREE daily email newsletter.